Likely Asteroid Debris Found upon Opening of Returned NASA Probe

The return capsule containing a sample collected from the asteroid Bennu in October 2020 by NASA’s OSIRIS-REx spacecraft is seen shortly after touching down in the desert at the Department of Defense's Utah Test and Training Range in Dugway, Utah, US September 24, 2023. (NASA/Keegan Barber/Handout via Reuters)
The return capsule containing a sample collected from the asteroid Bennu in October 2020 by NASA’s OSIRIS-REx spacecraft is seen shortly after touching down in the desert at the Department of Defense's Utah Test and Training Range in Dugway, Utah, US September 24, 2023. (NASA/Keegan Barber/Handout via Reuters)
TT

Likely Asteroid Debris Found upon Opening of Returned NASA Probe

The return capsule containing a sample collected from the asteroid Bennu in October 2020 by NASA’s OSIRIS-REx spacecraft is seen shortly after touching down in the desert at the Department of Defense's Utah Test and Training Range in Dugway, Utah, US September 24, 2023. (NASA/Keegan Barber/Handout via Reuters)
The return capsule containing a sample collected from the asteroid Bennu in October 2020 by NASA’s OSIRIS-REx spacecraft is seen shortly after touching down in the desert at the Department of Defense's Utah Test and Training Range in Dugway, Utah, US September 24, 2023. (NASA/Keegan Barber/Handout via Reuters)

After a seven-year wait, NASA scientists on Tuesday finally pried open a space probe carrying the largest asteroid samples ever brought back to Earth, finding black debris.

Researchers "found black dust and debris on the avionics deck of the Osiris-Rex science canister when the initial lid was removed today," the US space agency said, though without specifying whether they definitely belonged to the asteroid.

Scientists are eagerly awaiting researching the bulk of the sample, which will require "intricate disassembly" of the probe.

Osiris-Rex launched in 2016, landing on the asteroid Bennu and collected roughly nine ounces (250 grams) of dust from its rocky surface.

Even that small amount, NASA has said, should "help us better understand the types of asteroids that could threaten Earth."

It ended its 3.86-billion-mile (6.21-billion-kilometer) journey after touching down in the desert in the western state of Utah on Sunday, following a high-stakes, fiery descent through Earth's atmosphere.

The residue on the avionics deck found Tuesday was likely a result of issues during the collection, which NASA said were eventually solved, allowing the secure transfer of the sample.

The lid was opened in an airtight chamber at the Johnson Space Center in Houston, Texas.

A news conference is scheduled October 11 in which the bulk of the sample will be revealed to the public.

The analysis of the asteroid, scientists believe, will help researchers better understand the formation of the solar system and how Earth became habitable.

Most of the sample will be conserved for study by future generations. Roughly one-fourth will be immediately used in experiments, and a small amount will be sent to mission partners Japan and Canada.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”